HK1084338A1 - Pharmaceutical formulation comprising lanthanum compounds - Google Patents

Pharmaceutical formulation comprising lanthanum compounds

Info

Publication number
HK1084338A1
HK1084338A1 HK06106716.4A HK06106716A HK1084338A1 HK 1084338 A1 HK1084338 A1 HK 1084338A1 HK 06106716 A HK06106716 A HK 06106716A HK 1084338 A1 HK1084338 A1 HK 1084338A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical formulation
lanthanum compounds
lanthanum
compounds
formulation
Prior art date
Application number
HK06106716.4A
Other languages
English (en)
Inventor
Josesphine Christine Ferdinando
Robert Paul Haslam
Laura Anna Trespidi
Original Assignee
Shire Holdings Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34221462&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1084338(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Holdings Ag filed Critical Shire Holdings Ag
Publication of HK1084338A1 publication Critical patent/HK1084338A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
HK06106716.4A 2003-08-26 2006-06-12 Pharmaceutical formulation comprising lanthanum compounds HK1084338A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49756003P 2003-08-26 2003-08-26
US51707803P 2003-11-05 2003-11-05
PCT/CA2004/001563 WO2005018651A1 (fr) 2003-08-26 2004-08-26 Preparation pharmaceutique contenant des composes de lanthane

Publications (1)

Publication Number Publication Date
HK1084338A1 true HK1084338A1 (en) 2006-07-28

Family

ID=34221462

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06106716.4A HK1084338A1 (en) 2003-08-26 2006-06-12 Pharmaceutical formulation comprising lanthanum compounds

Country Status (29)

Country Link
US (2) US7465465B2 (fr)
EP (4) EP2792363B1 (fr)
JP (2) JP4896719B2 (fr)
KR (1) KR100830764B1 (fr)
CN (1) CN1871018B (fr)
AT (2) ATE460169T1 (fr)
AU (2) AU2004266050B2 (fr)
BR (1) BRPI0413394A8 (fr)
CA (1) CA2536959C (fr)
CY (2) CY1110241T1 (fr)
CZ (1) CZ17621U1 (fr)
DE (2) DE202004021169U1 (fr)
DK (5) DK1660104T3 (fr)
EA (2) EA012798B1 (fr)
ES (4) ES2592803T3 (fr)
FI (1) FI7568U1 (fr)
HK (1) HK1084338A1 (fr)
HU (2) HUE024906T2 (fr)
IL (2) IL173755A0 (fr)
IS (1) IS2893B (fr)
MX (1) MXPA06002257A (fr)
NO (1) NO342559B1 (fr)
NZ (1) NZ545633A (fr)
PL (4) PL2133084T3 (fr)
PT (4) PT2172205E (fr)
SG (1) SG145765A1 (fr)
SI (4) SI2792363T1 (fr)
WO (1) WO2005018651A1 (fr)
ZA (1) ZA200602213B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
ES2362271T3 (es) * 2001-04-23 2011-06-30 Shire International Licensing B.V. Uso de carbonato de lantano para la prevención de la enfermedad de cálculo renal.
US20060083791A1 (en) 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
SI2792363T1 (sl) 2003-08-26 2016-11-30 Shire Biopharmaceuticals Holdings Ireland Limited Farmacevtske formulacije, ki obsegajo lantanove spojine
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
CN101018555A (zh) * 2004-07-27 2007-08-15 夏尔制药公司 用羟基碳酸镧治疗高磷酸盐血症的方法
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
JP2008516971A (ja) * 2004-10-15 2008-05-22 アルテアーナノ，インコーポレーテッド 錠剤による負荷が軽減されるリン酸塩結合剤
ITME20040015A1 (it) 2004-12-07 2005-03-07 Vincenzo Savica Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
EP1698233A1 (fr) * 2005-03-01 2006-09-06 Bayer HealthCare AG Réduction de la digestibilité de phosphore dans la nutrition animale
CA2619643A1 (fr) * 2005-08-17 2007-02-22 Altairnano, Inc. Compositions et methodes de traitement de l'insuffisance renale chronique et d'autres etats chez des animaux domestiques
US20080069860A1 (en) * 2005-08-17 2008-03-20 Allison Wren Hyperphosphatemia in domestic animals: compositions and methods of treatment
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
CN100398112C (zh) * 2006-03-24 2008-07-02 辽宁诺康生物制药有限责任公司 一种治疗血磷酸盐过多症的药物及其制备方法
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
RU2471356C2 (ru) * 2007-07-31 2013-01-10 Карджилл, Инкорпорейтед Декстроза для прямого прессования
GB0720220D0 (en) 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
TWI468167B (zh) 2007-11-16 2015-01-11 威佛（國際）股份有限公司 藥學組成物
WO2009118760A2 (fr) * 2008-03-26 2009-10-01 Matrix Laboratories Limited Composition de lanthane
PL2389070T3 (pl) * 2009-01-21 2014-01-31 Mylan Inc Preparaty węglanu lantanu ulegające rozpadowi
WO2010106557A2 (fr) * 2009-03-20 2010-09-23 Panacea Biotec Limited Formulations pharmaceutiques stables comprenant du carbonate de lanthane anhydre et procédé pour la préparation de celui-ci
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
US20120219637A1 (en) * 2009-10-26 2012-08-30 Dhore Aniket Pharmaceutical compositions of lanthanum carbonate and process for the preparation thereof
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition
WO2011143475A1 (fr) 2010-05-12 2011-11-17 Spectrum Pharmaceuticals, Inc. Hydroxyde de carbonate de lanthane, oxycarbonate de lanthane, et procédés pour leur fabrication et méthodes pour leur utilisation
EP2441436A1 (fr) * 2010-10-13 2012-04-18 Fresenius Medical Care Deutschland GmbH Formule de liants de phosphate pour l'extraction simple
US8263119B2 (en) 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
US8697132B2 (en) 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
CN103127041A (zh) * 2012-02-23 2013-06-05 南京卡文迪许生物工程技术有限公司 含有醋酸镧的药物组合物及其制备方法和用途
DE102012209411A1 (de) * 2012-06-04 2013-12-05 Fim Biotech Gmbh Mineralische Verbindung zur Reduzierung von anorganischen Phosphaten, insbesondere im Rahmen einer Nierenersatztherapie
CN104473963B (zh) * 2014-12-24 2017-10-10 厦门科明达科技有限公司 稀土化学药碳酸镧咀嚼片的制备方法
JP2016147827A (ja) * 2015-02-12 2016-08-18 株式会社三和化学研究所 炭酸ランタン水和物を含有する医薬製剤
US10058569B2 (en) 2015-06-24 2018-08-28 Lupin Limited Lanthanum carbonate compositions
JP6093829B1 (ja) * 2015-10-02 2017-03-08 バイエル薬品株式会社 ランタン化合物を含む医薬組成物
JP6623753B2 (ja) * 2015-12-28 2019-12-25 ニプロ株式会社 炭酸ランタンを含む口腔内崩壊錠
CN107213126B (zh) * 2017-05-17 2020-06-23 西安棣加生物科技有限公司 一种3d打印技术制备治疗高磷血症的口腔速崩片的方法
CN108969497A (zh) * 2018-10-12 2018-12-11 沈阳华泰药物研究有限公司 一种碳酸镧片剂组合物及其制备方法
WO2021101461A1 (fr) * 2019-11-21 2021-05-27 Santa Farma İlaç Sanayi̇ A.Ş. Compositions pharmaceutiques solides orales comprenant de l'octahydrate de carbonate de lanthane
CN113244179B (zh) * 2021-05-21 2023-01-13 浙江仟源海力生制药有限公司 一种稳定性好的碳酸镧片剂及其制备方法和其应用
US20230123099A1 (en) * 2021-10-15 2023-04-20 Fertin Pharma A/S Dextrose tablets with improved mouthfeel
CN115813867A (zh) * 2022-12-01 2023-03-21 山东齐都药业有限公司 碳酸镧冻干片及其制备方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54155675A (en) * 1978-05-30 1979-12-07 Matsushita Electronics Corp Small-sized fluorescent lamp
JPH06705B2 (ja) 1985-12-19 1994-01-05 旭化成工業株式会社 リン酸イオンの固定化剤
US4822594A (en) 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
US4877735A (en) 1987-06-19 1989-10-31 Takeda Chemical Industries, Ltd. Process for producing 2-keto-L-gulonic acid
JPS6485088A (en) 1987-06-19 1989-03-30 Takeda Chemical Industries Ltd Production of 2-keto-l-gulonic acid
DE3724188C2 (de) 1987-07-17 1995-05-18 Heinz Dr Gries Metallhaltige Oligosaccharid-Polysulfate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel
ATE147261T1 (de) * 1992-01-13 1997-01-15 Pfizer Verfahren zur herstellung von tabletten mit hoher festigkeit
WO1995031963A1 (fr) 1994-05-20 1995-11-30 Janssen Pharmaceutica N.V. Tablettes de flubendazole a mastiquer pour animaux de compagnie
CA2128199C (fr) * 1994-07-15 1997-02-04 Bernard Charles Sherman Compositions pharmaceutiques, solides, stables, renfermant du maleate d'enalapril
JP3591886B2 (ja) 1994-09-05 2004-11-24 シーシーアイ株式会社 希土類元素集積微生物
GB9506126D0 (en) 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
US20040043971A1 (en) 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US6074672A (en) 1996-06-28 2000-06-13 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Powdered cosmetic compositions containing silicone elastomers
GB9720061D0 (en) * 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
GB9816899D0 (en) * 1998-08-05 1998-09-30 Boots Co Plc Therapeutic agents
US6270790B1 (en) * 1998-08-18 2001-08-07 Mxneil-Ppc, Inc. Soft, convex shaped chewable tablets having reduced friability
JP2000173537A (ja) * 1998-09-29 2000-06-23 Toshiba Lighting & Technology Corp 低圧水銀蒸気放電灯および照明装置
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6160016A (en) * 1999-12-22 2000-12-12 Wisconsin Alumni Research Foundation Phosphorus binder
GB0008392D0 (en) 2000-04-05 2000-05-24 Unilever Plc Process for the production of a deodorant or antiperspirant product
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
US20020057059A1 (en) * 2000-07-28 2002-05-16 Kazuhisa Ogishi Fluorescent lamp, self-ballasted fluorescent lamp and lighting apparatus
JP2002047210A (ja) 2000-08-04 2002-02-12 Nihon Medi Physics Co Ltd 尿路結石防止用組成物
JP4612183B2 (ja) 2000-12-27 2011-01-12 株式会社ヤクルト本社 皮膚外用組成物及びその製造方法
JP4612180B2 (ja) 2000-12-19 2011-01-12 株式会社ヤクルト本社 皮膚外用剤
EP1344528B1 (fr) 2000-12-19 2008-10-08 Kabushiki Kaisha Yakult Honsha Preparations externes pour la peau et leur procede de production
US20020122823A1 (en) 2000-12-29 2002-09-05 Bunick Frank J. Soft tablet containing dextrose monohydrate
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
ES2362271T3 (es) * 2001-04-23 2011-06-30 Shire International Licensing B.V. Uso de carbonato de lantano para la prevención de la enfermedad de cálculo renal.
GB0201607D0 (en) 2002-01-24 2002-03-13 Gamlen Michael J D Formulation for the administration of medicinal substances
AU2003231777C1 (en) * 2002-04-29 2009-10-29 Supernus Pharmaceuticals, Inc. Pharmaceutical formulations with improved bioavailability
WO2003094933A2 (fr) 2002-05-08 2003-11-20 Shire Holding Ag Methode de traitement utilisant des composes de lanthane
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
AU2003282867A1 (en) 2002-10-22 2004-05-13 Genzyme Corporation Amine polymers for promoting bone formation
US7381428B2 (en) 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
SI2792363T1 (sl) * 2003-08-26 2016-11-30 Shire Biopharmaceuticals Holdings Ireland Limited Farmacevtske formulacije, ki obsegajo lantanove spojine
US7449605B2 (en) 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7385012B2 (en) 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7459502B2 (en) 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7335795B2 (en) 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7608674B2 (en) 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7545784B2 (en) * 2004-02-11 2009-06-09 Yahoo! Inc. System and method for wireless communication between previously known and unknown users
US8282960B2 (en) 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
US7854924B2 (en) 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
GB2430367B (en) 2004-03-30 2009-08-05 Ilypsa Inc Ion binding polymers and uses thereof
US8192758B2 (en) 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
CN101018555A (zh) * 2004-07-27 2007-08-15 夏尔制药公司 用羟基碳酸镧治疗高磷酸盐血症的方法
AR061727A1 (es) * 2006-06-30 2008-09-17 Schering Corp Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
WO2009118760A2 (fr) 2008-03-26 2009-10-01 Matrix Laboratories Limited Composition de lanthane

Also Published As

Publication number Publication date
FIU20060387U0 (fi) 2006-09-22
PT2172205E (pt) 2014-07-17
SI2133084T1 (sl) 2015-07-31
HUE024906T2 (en) 2016-02-29
AU2009202429B2 (en) 2012-03-22
NO20061347L (no) 2006-05-15
BRPI0413394A8 (pt) 2016-03-08
DK1660104T3 (da) 2010-06-21
JP4896719B2 (ja) 2012-03-14
EP2792363A1 (fr) 2014-10-22
NZ545633A (en) 2009-07-31
BRPI0413394A (pt) 2006-10-17
PT2792363T (pt) 2016-09-26
KR20060118420A (ko) 2006-11-23
EP2172205B1 (fr) 2014-06-18
NO342559B1 (no) 2018-06-18
EP1660104B1 (fr) 2010-03-10
EP1660104A1 (fr) 2006-05-31
EP2172205A1 (fr) 2010-04-07
CY1118211T1 (el) 2017-06-28
DE602004025950D1 (de) 2010-04-22
AU2009202429A1 (en) 2009-07-09
PL1660104T3 (pl) 2010-08-31
US7465465B2 (en) 2008-12-16
HUE029382T2 (en) 2017-02-28
ES2478258T3 (es) 2014-07-21
EP2133084B1 (fr) 2015-02-18
DK200600252U1 (da) 2007-01-12
FI7568U1 (fi) 2007-07-17
US20090017133A1 (en) 2009-01-15
WO2005018651A1 (fr) 2005-03-03
CY1110241T1 (el) 2015-01-14
SI1660104T1 (sl) 2010-08-31
EA012798B1 (ru) 2009-12-30
CN1871018A (zh) 2006-11-29
AT9809U1 (de) 2008-04-15
ES2592803T3 (es) 2016-12-01
DK2172205T3 (da) 2014-07-14
EA200970709A1 (ru) 2010-04-30
JP2010248247A (ja) 2010-11-04
EA200600479A1 (ru) 2006-08-25
KR100830764B1 (ko) 2008-05-20
ES2532389T3 (es) 2015-03-26
DE202004021169U1 (de) 2007-03-01
DK2792363T3 (da) 2016-09-26
IS8353A (is) 2006-03-15
PT1660104E (pt) 2010-06-15
PL2172205T3 (pl) 2015-01-30
DK200600252U4 (da) 2007-11-23
ATE460169T1 (de) 2010-03-15
EP2133084A3 (fr) 2010-02-03
IS2893B (is) 2014-09-15
PL2133084T3 (pl) 2015-08-31
EP2133084A2 (fr) 2009-12-16
CA2536959C (fr) 2011-08-02
AU2004266050B2 (en) 2009-06-18
ZA200602213B (en) 2009-04-29
DK2133084T3 (en) 2015-04-13
JP2007503400A (ja) 2007-02-22
MXPA06002257A (es) 2006-05-17
EP2792363B1 (fr) 2016-06-29
SG145765A1 (en) 2008-09-29
IL235371B (en) 2018-08-30
ES2343354T3 (es) 2010-07-29
SI2172205T1 (sl) 2014-10-30
CZ17621U1 (cs) 2007-06-25
PL2792363T3 (pl) 2017-01-31
CA2536959A1 (fr) 2005-03-03
PT2133084E (pt) 2015-04-16
SI2792363T1 (sl) 2016-11-30
US20050079135A1 (en) 2005-04-14
EP1660104A4 (fr) 2006-10-18
CN1871018B (zh) 2011-11-02
IL173755A0 (en) 2006-07-05
AU2004266050A1 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
IL173755A0 (en) Pharmaceutical formulation comprising lanthanum compounds
GB0323908D0 (en) Pharmaceutical foam formulation
IL173808A0 (en) Pharmaceutical liposomal formulations
IL172824A0 (en) Pharmaceutical formulations
GB0302671D0 (en) Pharmaceutical formulations
EP1631239A4 (fr) Compositions pharmaceutiques contenant des composes actifs de vitamine d
GB0300427D0 (en) Pharmaceutical composition
HK1084670A1 (en) Pharmaceutical compositions comprising cabbinochreme type compounds
HUP0303948A2 (hu) Szájban diszpergálódó szilárd gyógyszerforma
EP1699458A4 (fr) Composition pharmaceutique
GB0316206D0 (en) Pharmaceutical formulation
GB0302672D0 (en) Pharmaceutical formulations
GB0316341D0 (en) Pharmaceutical formulations
GB0300885D0 (en) Pharmaceutical composition
IL172304A0 (en) Pharmaceutical compositions comprising active vitamin d compounds
GB0306933D0 (en) Pharmaceutical composition
GB0307862D0 (en) Pharmaceutical composition
GB0307864D0 (en) Pharmaceutical composition
GB0310881D0 (en) Pharmaceutical formulation
AU2003238900A8 (en) Pharmaceutical formulation
GB0302435D0 (en) Pharmaceutical formulation
GB0316335D0 (en) Pharmaceutical formulations
GB0225041D0 (en) Pharmaceutical formulation
AU2003904627A0 (en) Pharmaceutical Formulation
GB0316338D0 (en) Pharmaceutical formulations